Clinical trial · Interventional
Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma
Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma
NCT01747642CI-TRIAL-00008659unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oncoxin | Dietary Supplement | — | UNRESOLVED |
| Suranix | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Oncoxin
- description
- Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
- interventionNames
- Dietary Supplement: Oncoxin
- type
- ACTIVE_COMPARATOR
- label
- Oncoxin & Suranix
- description
- Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
- interventionNames
- Dietary Supplement: Oncoxin
- Drug: Suranix
- type
- NO_INTERVENTION
- label
- Supportive treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with HCC irrespective of etiology, age, gender and status of underlying liver disease. * Patients with HCC who are not suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who have evidence of tumor metastasis * Patients with HCC who are voluntarily unwilling to take established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC in whom all possible treatment options have been exhausted. Exclusion Criteria: * Patients with HCC who are suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who have no evidence of tumor metastasis * Patients with HCC who are willing to take established modalities of treatment i.e. surgery and/or chemotherapy. * Patients with HCC who are voluntarily unwilling to be included in the trial
References
Publications (0)
Data not yet available
No reference posted for this study.